Cargando…
Selegiline reduces daytime sleepiness in patients with Parkinson's disease
OBJECTIVES: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119812/ https://www.ncbi.nlm.nih.gov/pubmed/33759401 http://dx.doi.org/10.1002/brb3.1880 |
_version_ | 1783691933769531392 |
---|---|
author | Gallazzi, Marco Mauri, Marco Bianchi, Maria Laura Riboldazzi, Giulio Princiotta Cariddi, Lucia Carimati, Federico Rebecchi, Valentina Versino, Maurizio |
author_facet | Gallazzi, Marco Mauri, Marco Bianchi, Maria Laura Riboldazzi, Giulio Princiotta Cariddi, Lucia Carimati, Federico Rebecchi, Valentina Versino, Maurizio |
author_sort | Gallazzi, Marco |
collection | PubMed |
description | OBJECTIVES: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence. METHODS: In the present study, we retrospectively identified 45 Parkinson's disease patients (21 females and 24 males) among those referred to the PD Center in Varese that (a) showed excessive daytime sleepiness, usually developed after the introduction of a dopamine agonist, (b) were given selegiline 10 mg to improve their treatment schedule independently of excessive sleepiness, and (c) in whom the Epworth Sleepiness Scale (ESS) and the Parkinson's Disease Sleep Scale (PDSS) scores were available both before and 3 months after the introduction of selegiline. RESULTS: We compared the corresponding scores (ESS, PDSS, and UPDRS III) evaluated before and 3 months after the introduction of selegiline by the nonparametric Mann–Whitney U test: The differences showed a statistically significant improvement of somnolence but no change in the UPDRS III scores. CONCLUSION: Despite some limitations, our data suggest that selegiline may be a valuable add‐on therapy in PD patients to reduce their daytime somnolence. |
format | Online Article Text |
id | pubmed-8119812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81198122021-05-20 Selegiline reduces daytime sleepiness in patients with Parkinson's disease Gallazzi, Marco Mauri, Marco Bianchi, Maria Laura Riboldazzi, Giulio Princiotta Cariddi, Lucia Carimati, Federico Rebecchi, Valentina Versino, Maurizio Brain Behav Original Research OBJECTIVES: Excessive daytime sleepiness (EDS) affects a large percentage of Parkinson's disease (PD) patients, and it is enhanced by dopamine agonist drugs. Currently, there is no treatment of choice for EDS in PD. Our aim was to check the clinical impression that some patients who were given selegiline, a selective inhibitor of monoamine oxidase B, experienced an improvement in their daytime somnolence. METHODS: In the present study, we retrospectively identified 45 Parkinson's disease patients (21 females and 24 males) among those referred to the PD Center in Varese that (a) showed excessive daytime sleepiness, usually developed after the introduction of a dopamine agonist, (b) were given selegiline 10 mg to improve their treatment schedule independently of excessive sleepiness, and (c) in whom the Epworth Sleepiness Scale (ESS) and the Parkinson's Disease Sleep Scale (PDSS) scores were available both before and 3 months after the introduction of selegiline. RESULTS: We compared the corresponding scores (ESS, PDSS, and UPDRS III) evaluated before and 3 months after the introduction of selegiline by the nonparametric Mann–Whitney U test: The differences showed a statistically significant improvement of somnolence but no change in the UPDRS III scores. CONCLUSION: Despite some limitations, our data suggest that selegiline may be a valuable add‐on therapy in PD patients to reduce their daytime somnolence. John Wiley and Sons Inc. 2021-03-23 /pmc/articles/PMC8119812/ /pubmed/33759401 http://dx.doi.org/10.1002/brb3.1880 Text en © 2021 The Authors. Brain and Behavior published by Wiley Periodicals LLC https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Gallazzi, Marco Mauri, Marco Bianchi, Maria Laura Riboldazzi, Giulio Princiotta Cariddi, Lucia Carimati, Federico Rebecchi, Valentina Versino, Maurizio Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title | Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title_full | Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title_fullStr | Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title_full_unstemmed | Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title_short | Selegiline reduces daytime sleepiness in patients with Parkinson's disease |
title_sort | selegiline reduces daytime sleepiness in patients with parkinson's disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119812/ https://www.ncbi.nlm.nih.gov/pubmed/33759401 http://dx.doi.org/10.1002/brb3.1880 |
work_keys_str_mv | AT gallazzimarco selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT maurimarco selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT bianchimarialaura selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT riboldazzigiulio selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT princiottacariddilucia selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT carimatifederico selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT rebecchivalentina selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease AT versinomaurizio selegilinereducesdaytimesleepinessinpatientswithparkinsonsdisease |